Gilead Sciences (NASDAQ:GILD) has been given a $88.00 price objective by stock analysts at Mizuho in a note issued to investors on Friday, TipRanks reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price objective indicates a potential upside of 32.61% from the stock’s current price.
A number of other equities analysts have also commented on the stock. Wells Fargo & Co lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $95.00 to $68.00 in a research report on Monday, February 11th. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, April 22nd. Citigroup restated a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a research report on Tuesday, February 5th. Raymond James set a $83.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Friday, May 3rd. Finally, ValuEngine lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. Nine investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $81.61.
NASDAQ:GILD traded up $0.58 on Friday, reaching $66.36. The stock had a trading volume of 5,922,988 shares, compared to its average volume of 7,334,711. The firm has a market cap of $83.25 billion, a PE ratio of 10.79, a price-to-earnings-growth ratio of 0.79 and a beta of 1.14. Gilead Sciences has a 1-year low of $60.32 and a 1-year high of $79.61. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.23. The firm had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.48 earnings per share. On average, research analysts expect that Gilead Sciences will post 6.6 EPS for the current fiscal year.
In other news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $62.61, for a total transaction of $169,047.00. Following the transaction, the director now directly owns 57,560 shares in the company, valued at $3,603,831.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the transaction, the director now owns 34,669 shares in the company, valued at $2,270,126.12. The disclosure for this sale can be found here. Insiders have sold 47,670 shares of company stock worth $3,142,526 over the last quarter. 0.20% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the company. B. Riley Wealth Management Inc. lifted its holdings in Gilead Sciences by 2.9% in the first quarter. B. Riley Wealth Management Inc. now owns 6,576 shares of the biopharmaceutical company’s stock valued at $428,000 after buying an additional 184 shares during the period. Weiss Asset Management LP acquired a new position in Gilead Sciences in the first quarter valued at approximately $205,000. Horizon Investments LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $3,765,000. Laurel Wealth Advisors Inc. lifted its holdings in Gilead Sciences by 13.8% in the first quarter. Laurel Wealth Advisors Inc. now owns 10,761 shares of the biopharmaceutical company’s stock valued at $700,000 after buying an additional 1,307 shares during the period. Finally, Redwood Investment Management LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $272,000. Institutional investors own 79.94% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Recommended Story: How is inflation measured?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.